Natera, Inc. (NASDAQ:NTRA) Insider Sells $3,137,700.00 in Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) insider Daniel Rabinowitz sold 30,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $104.59, for a total transaction of $3,137,700.00. Following the transaction, the insider now directly owns 204,495 shares of the company’s stock, valued at approximately $21,388,132.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Daniel Rabinowitz also recently made the following trade(s):

  • On Tuesday, April 23rd, Daniel Rabinowitz sold 787 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $71,916.06.
  • On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The shares were sold at an average price of $89.01, for a total value of $1,827,019.26.
  • On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63.

Natera Trading Up 10.2 %

Shares of NASDAQ:NTRA traded up $9.74 during trading on Friday, hitting $105.29. 3,499,280 shares of the company’s stock were exchanged, compared to its average volume of 1,084,895. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $108.32. The firm has a 50-day moving average price of $92.32 and a two-hundred day moving average price of $71.27. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The firm has a market cap of $12.71 billion, a P/E ratio of -27.78 and a beta of 1.38.

Natera (NASDAQ:NTRAGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. During the same quarter in the previous year, the company earned ($1.23) EPS. Natera’s revenue was up 52.1% on a year-over-year basis. Equities analysts predict that Natera, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on NTRA shares. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research report on Friday, April 5th. Piper Sandler increased their target price on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Stephens reaffirmed an “overweight” rating and issued a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. TD Cowen boosted their target price on shares of Natera from $123.00 to $137.00 and gave the company a “buy” rating in a research note on Friday. Finally, Craig Hallum assumed coverage on shares of Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.13.

View Our Latest Stock Report on NTRA

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Natera by 0.7% during the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after purchasing an additional 72,848 shares during the period. JPMorgan Chase & Co. grew its holdings in Natera by 0.9% during the third quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock valued at $334,388,000 after purchasing an additional 67,102 shares during the period. Kynam Capital Management LP grew its holdings in Natera by 3.6% during the third quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock valued at $132,912,000 after purchasing an additional 103,668 shares during the period. RTW Investments LP grew its holdings in Natera by 1.5% during the third quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company’s stock valued at $117,341,000 after purchasing an additional 40,000 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Natera by 52.0% in the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock valued at $111,930,000 after buying an additional 865,404 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.